usp-800-hazardous-drug-handling-guide

SOSCLEANROOM | HAZARDOUS DRUGS & CONTAMINATION CONTROL

USP <800>: Hazardous-Drug Handling, Containment & Practical Compliance Readiness.

A practical technical guide for hospital pharmacies, oncology programs, compounders, EHS teams and procurement. Understand the 2024 NIOSH hazardous-drug list, containment engineering, assessment of risk, two-pair chemotherapy gloving, sterile versus nonsterile preparation, four cleaning stages, spill response, surface sampling and documentation. Explore direct SOSCleanroom product examples with qualification cautions.

Compare handling tasks ↓ Product selection ↓ Readiness checklist ↓

Purpose & scope

Hazardous-drug safety is a complete exposure-control system.

USP <800> addresses the risks of exposure to hazardous drugs (HDs) for workers, patients and the environment. Handling reaches far beyond sterile compounding: it begins with receipt and unpacking and continues through storage, preparation, dispensing, administration, transportation, spill response and disposal. A strong program identifies relevant drugs, evaluates the way each is handled and proves that engineering, personnel, cleaning and waste controls work together.

Inventory

Know what is hazardous

Maintain an entity-specific, current HD list with ownership, updates and product/formulation details.

Exposure

Assess actual handling

Evaluate dosage form, drug toxicity, possible release, packaging, manipulation and task-specific risk.

Containment

Control the source

Select proper containment engineering for tasks that generate aerosols, powders, droplets or surface residue.

PPE

Protect the operator

Select ASTM D6978 chemotherapy gloves, protective gowns and other PPE based on the activity and required baseline.

Cleaning

Control surface residue

Separate deactivation, decontamination, cleaning and (for sterile operations) disinfection; select agents specific to the task.

Quality

Document and improve

Keep SOPs, training, certification, inspection, incidents, monitoring investigations and supplier qualification traceable.

Hazard identification

Use the current NIOSH drug list and correct table definitions.

The current NIOSH publication is the NIOSH List of Hazardous Drugs in Healthcare Settings, 2024 (NIOSH Publication 2025-103). It supersedes the 2016 list. The CDC also maintains updates and notices for hazardous drugs with manufacturer special-handling information. A facility should compare the current NIOSH publication and subsequent notices with its actual formulary and manufacturer labeling, rather than relying on a static legacy spreadsheet.

Document / category	Practical meaning	Action for the pharmacy
NIOSH 2024 Table 1	Includes drugs with manufacturer special-handling information and/or specified high-concern carcinogenicity criteria; it is not simply a table headed “antineoplastics.”	Identify whether a Table 1 drug is an antineoplastic by the relevant AHFS classification; do not equate every Table 1 entry with an antineoplastic.
NIOSH 2024 Table 2	Contains other drugs meeting NIOSH hazardous-drug criteria under the updated table arrangement.	Determine drug/formulation exposure and the applicable assessment-of-risk pathway.
Manufacturer package insert / SDS	May indicate special handling and exposure controls, including for newly approved drugs.	Keep package insert, task assessment and formulary update process current.
USP <800> 2020 revision bulletin	For purposes of USP <800>, “antineoplastic” refers to antineoplastic drugs included in current NIOSH Table 1.	Avoid using outdated 2016 table descriptions to decide containment.

Primary sources: NIOSH 2024 list and updates and USP <800> FAQ questions 7–11.

Assessment of risk

Decide by drug, dosage form and manipulation—not labels alone.

An assessment of risk (AoR) is a controlled decision about a particular drug and the way it is handled—not a blanket permission to relax safety controls. USP’s 2026 FAQ describes consideration of drug type, dosage form, exposure likelihood, packaging and manipulation. HD active pharmaceutical ingredients (APIs) and qualifying NIOSH Table 1 antineoplastics that require manipulation are not equivalent to unopened final dosage forms.

Handling situation	Containment decision	Required documentation focus
HD API used as a compounding component	Follow the applicable full HD containment requirements; an AoR cannot be used simply to bypass controls for an API.	Drug identity, formulation, powder/solution transfer and containment.
NIOSH Table 1 antineoplastic requiring HD manipulation	Apply the chapter containment provisions; distinguish this from handling a final dosage form.	Manipulations, worker exposure, equipment and PPE.
Commercial final dosage form not requiring further manipulation beyond counting/repackaging	USP FAQ describes an AoR pathway, subject to manufacturer handling instructions and circumstances.	Exact dosage form, package integrity, possible breakage and precautions.
Other HDs eligible for AoR, including appropriate Table 2 drugs	Evaluate alternatives for containment and work practices based on the particular drug and operation.	Written criteria, approved controls, training, review interval and reassessment.

Lifecycle control matrix

Protect every handoff from receipt to disposal.

An HD program should map every handling event to its typical exposure pathway, engineering controls, PPE and evidence. The following is an operational planning matrix, not a substitute for the chapter’s exact requirements or task-specific evaluation.

Stage	Primary risk	Baseline safeguards / questions	Records
Receipt & unpacking	Broken primary containers, contaminated exteriors and spills.	Inspect packaging, use designated unpacking location, appropriate chemotherapy gloves and damage response.	Receiving log, training and incident record.
Storage	Cross-contamination, leaks and uncontrolled refrigeration.	Correct segregation, negative-pressure provisions where applicable and suitable containment.	Inventory, pressure monitoring and inspections.
Nonsterile compounding	Powders, dust, splashes and contaminated tools.	Appropriate HD C-PEC/C-SEC, two ASTM D6978 glove pairs, gowning, work practices.	Certification, garbing and cleaning logs.
Sterile compounding	HD exposure plus microbial/particulate risk.	Externally vented ISO 5 C-PEC, suitable C-SEC, sterile technique, two chemotherapy-glove barriers.	USP 797 records plus USP 800 records.
Dispensing / transport	Leakage, breakage or transfer of HD residue.	Protective packaging, labeling, secure transport and staff instructions.	Transport/packaging SOPs, exceptions.
Administration	Connection/disconnection exposure, drips and disposal.	Task PPE, compatible CSTD where required and available, spill and waste procedures.	Training, incidents and waste controls.
Cleaning / waste	Redistribution of residual HD and exposure during removal.	Chemical-specific cleaning sequence, dedicated materials, correct disposal.	Cleaning/sampling records, disposal logs.

Primary and secondary controls

C-PEC, C-SEC and C-SCA solve different problems.

Understand the three containment terms before selecting equipment. C-PEC is the containment primary engineering control that directly protects the user and environment at the source of HD manipulation. C-SEC is the containment secondary engineering control—the surrounding room or controlled environment. C-SCA is a containment segregated compounding area, a restricted space used under a limited pathway.

C-PEC

Source containment

A biological safety cabinet, compounding aseptic containment isolator or appropriate containment ventilated enclosure can be a C-PEC, depending on the sterile/nonsterile operation and its qualified design.

C-SEC

Room containment

Provides required room separation, airflow, pressure control, external exhaust and air-change performance for the compounding operation.

C-SCA

Limited segregated area

The 2026 USP FAQ clarifies that only Category 1 hazardous-drug CSPs can be prepared in a C-SCA. This is not a blanket location for all sterile HD compounding.

BSC

Biological safety cabinet

For sterile HD work, the appropriate Class II BSC is one qualifying C-PEC type when installed and exhausted as required.

CACI

Compounding aseptic containment isolator

Combines containment and aseptic protection when fully qualified; its glove/sleeve system needs special attention and it belongs in a compliant C-SEC.

LAFW / CAI

Not worker containment devices

A laminar airflow workbench or conventional compounding aseptic isolator is not a substitute for required HD containment. The USP FAQ identifies narrow AoR-qualified exceptions for eligible other HDs.

For sterile manipulation of HDs, the C-PEC must provide ISO Class 5 or better air quality and be externally vented. A CACI does not waive the C-SEC requirement. See USP questions 32–39.

Facility engineering

Airflow, negative pressure and exhaust must function continuously.

HD containment rooms are designed to retain contamination and prevent release into adjacent spaces. USP’s 2026 FAQ says that the C-SEC must maintain negative pressure of 0.01–0.03 inches water column relative to adjacent areas and suitable air changes continuously. Published examples distinguish 12 and 30 air changes per hour (ACPH) for different room arrangements. These are design/application-specific—not permission to switch ventilation off after hours.

Room or system parameter	Planning interpretation	Verify with qualified facilities team
Pressure differential	Appropriate continuous negative pressure relative to adjacent spaces.	Gauge location, alarm and trending, calibration, response to excursions.
Air changes / external exhaust	Requirement depends on room type and use; exhaust must leave the building when external venting is required.	C-SEC engineering specification, balancing and testing.
Sterile HD buffer room	Additional USP <797> ISO classifications and personnel/material flow apply.	Room certification, environmental monitoring, entry controls.
Unclassified C-SCA	Used only under the limited Category 1 HD CSP pathway, with the applicable containment and beyond-use conditions.	Eligibility, physical separation, sink position and air-change records.
Storage refrigeration	The USP FAQ addresses dedicated HD refrigerator placement in an appropriate negative-pressure environment for applicable inventory.	Inventory-by-drug, location, ventilation and dedicated-equipment rules.

Receiving and unpacking

The first HD-control boundary begins before the drug reaches the pharmacy.

When an HD arrives, the source of potential contamination may be the outside of the package, broken vials or leaking containers. The receiving area should have an accessible damage response plan and an approved method for evaluating package integrity without transferring a suspect shipment into cleaner areas.

Step 01

Identify the shipment

Check manifest, HD designation, manufacturer handling warnings and whether the package has protective containment.

Step 02

Inspect before unpacking

Determine damage, leakage or missing protection without touching suspect material without proper PPE.

Step 03

Use the designated unpacking location

USP FAQ states NIOSH Table 1 antineoplastics and HD APIs are unpacked in a neutral or negative-pressure area; avoid positive-pressure or sterile compounding rooms.

Step 04

Use the correct gloves

For unpacking Table 1 antineoplastic HDs, the USP FAQ requires at least one ASTM D6978 chemotherapy-glove pair; other HD tasks follow documented policy.

Step 05

Contain damage

Isolate suspect packages, use trained personnel and spill response procedures; document exposure/receiving exceptions.

See USP questions 68–73 on receiving.

Designated storage

Storage conditions must control HD residue and handling risk.

Store hazardous drugs using designated areas, appropriate separation and inventory controls. HD APIs and qualifying antineoplastics requiring manipulation call for specific segregation/ventilation decisions. Refrigerated HDs are a frequent weak point: a regular refrigerator located in an unsuitable room is not automatically acceptable.

Segregation

Define and label inventory

Separate stock as required and prevent HD material from sharing clean non-HD supply pathways without an approved process.

Refrigeration

Review negative-pressure requirements

The applicable NIOSH Table 1 antineoplastic refrigerated inventory requires dedicated refrigeration in a negative-pressure area meeting the published air-change expectation.

Pressure

Maintain when closed

Negative pressure is a continuous containment feature, not only a when-staff-are-present setting.

Cleaning

Specify shelf and bin methods

Make shelves smooth, impervious and cleanable, with an approved decontamination schedule and handling plan.

Inventory

Control packaging failures

Store damaged or quarantined products in a secure designated manner and investigate before release.

Training

Teach access rules

Staff outside compounding, including receiving, housekeeping and facilities teams, need activity-appropriate instructions.

Sterile hazardous-drug compounding

Aseptic protection and HD containment operate together.

A sterile HD preparation must meet both USP <797> aseptic-compounding expectations and USP <800> hazardous-drug containment requirements. Compounding inside an ISO Class 5 area does not prove worker containment, and a negative-pressure room by itself does not demonstrate a sterile critical environment.

Sterile HD decision	Practical requirement	Verify
Critical air and C-PEC	Qualified externally vented C-PEC providing ISO 5 or better air quality.	Equipment certificate, airflow/containment function and external venting.
Room conditions	Compliant C-SEC, negative pressure and appropriate room classification as applicable.	Continuous operation, certification and monitoring records.
Gloves	Two ASTM D6978 chemotherapy-glove layers; the outer glove must meet sterile-compounding protection requirements.	Drug-specific permeation and sterile presentation of outer pair.
Garbing and PPE	Applicable HD gown, head/hair and shoe-cover program, with safe entry/exit practices.	Gown permeability documentation and approved donning/doffing.
Aseptic control	USP <797> personnel competence, contamination control, disinfection and CSP requirements still apply.	Media fills, gloved fingertip testing, cleaning and environmental data.
C-SCA pathway	Limited to Category 1 HD CSP preparation under the clarification in the 2026 FAQ.	C-SCA eligibility and local approval.

See SOSCleanroom USP 797 sterile compounding guide and USP 800 C-SCA clarification.

Nonsterile hazardous-drug compounding

Powders and concentrated ingredients demand source containment.

Nonsterile HD compounding can still create substantial occupational exposure, especially when manipulating powdered APIs, opening capsules, crushing tablets, or mixing concentrated ingredients. Use the appropriate containment control to keep material from becoming airborne or contacting skin, clothing and work surfaces.

Powders and APIs

Contain particle-generating steps

Weighing, opening or mixing powders requires containment controls appropriate to the API and operation.

Equipment

Dedicated product-contact tools

Equipment that directly contacts HD material is dedicated for HD use. Other equipment may require approved deactivation/decontamination/cleaning before leaving the area.

PPE

Two chemotherapy-glove pairs

Use gowning and two ASTM D6978-tested glove layers for HD compounding, sterile or nonsterile.

Area

Document containment classification

Nonsterile HD C-PEC and C-SEC ventilation and spacing rules are not interchangeable with sterile HD requirements.

SOP

Control every stage

Identify who prepares, where each step occurs, how materials transfer and which tools are discarded or cleaned.

Waste

Contain after the task

Do not allow visible powder/residue to move into non-HD processing zones.

For details on powder handling and nonsterile presterilization steps, consult USP FAQ questions 63–66.

Supplemental containment

A CSTD is an additional control—not a substitute for engineering.

Closed-system drug-transfer devices (CSTDs) add a supplementary containment mechanism; they do not replace a required containment engineering control. The 2026 USP FAQ distinguishes the two major activities: recommended during compounding and required for administering NIOSH Table 1 antineoplastic HDs when the dosage form allows. Compatibility with the particular drug and connection system remains necessary.

Question	Answer	Critical limit
Does a CSTD replace a BSC or CACI?	No.	A CSTD is supplemental; required C-PEC and room controls still apply.
Is a CSTD mandatory for compounding?	The USP 2026 FAQ says it is recommended, not universally required.	Check current rules and institutional policy.
Is a CSTD mandatory for administering Table 1 antineoplastic HDs?	Yes, when the dosage form allows.	Must be physically and chemically compatible with the actual HD.
Are all CSTDs equally qualified?	No automatic equivalence.	Review device-specific performance and interface requirements.

Glove protection

Two tested glove layers are a core HD-compounding control.

USP’s January 2026 FAQ confirms two pairs of chemotherapy gloves meeting ASTM D6978 for compounding sterile and nonsterile hazardous drugs. Powder-free construction, material chemistry, drug-specific permeation, cuff length, size and proper layering still need separate evaluation. A sterile glove may not be chemotherapy tested; a chemotherapy-tested glove may not be sterile.

Glove use	Practical selection	Important qualification
Unpacking Table 1 antineoplastic HDs	At least one ASTM D6978 chemotherapy-glove pair under the USP FAQ.	Do not confuse this with the two-pair compounding rule.
HD sterile and nonsterile compounding	Two ASTM D6978-tested glove pairs.	Outer pair sterile for sterile compounding, with the appropriate gown/cuff interface.
Administration of Table 1 antineoplastic HDs	Two ASTM D6978-tested glove pairs under the USP FAQ.	Additional gown requirement for injectable Table 1 antineoplastic HDs.
Handling other HDs	PPE per the facility risk-based policies and applicable chapter.	Document drug/task-specific rationale.
CACI sterile HD preparation	USP FAQ describes one chemotherapy-glove layer on sleeve assembly and another over it.	Additional hand glove may be used under local equipment/policy arrangement.

Candidate products for documented evaluation: Ansell TouchNTuff 93-700, Ansell BioClean Excell BEXS, Ansell BioClean Emerald BENS and TechNiGlove STN200P. Do not assume interchangeability. Obtain the exact manufacturer drug-permeation results and sterile labeling before approval. More detail: complete glove selection guide.

Protective apparel

Select gowns for chemical permeability—not just sterility or splash ratings.

Gowns used for hazardous-drug activities must be demonstrated to resist permeability by the HDs likely to be encountered. A conventional isolation gown, AAMI fluid-barrier level or sterile packaging claim alone does not prove the chemotherapy permeability performance needed for the task. ASTM F3267-22 is a relevant newer specification for chemotherapy protective clothing, but current model-specific test data must still be reviewed.

Gown

Barriers and construction

Review HD permeability evidence, seam construction, cuffs and back closure; check the manufacturer claims for the exact SKU.

Shoe covers

Double-layer practices

USP FAQ includes two pairs of shoe covers for HD compounding; use a controlled doffing location.

Head / hair

Controlled protective coverage

Choose head and hair coverings consistent with HD and sterile area protocols and prevent exposed gaps.

Eye / face

Splash-specific protection

Add eye/face PPE when the task assessment indicates splash or spill exposure; select compatible equipment.

Respiratory protection

Task-based, regulated choice

Respirator selection follows exposure assessment and applicable occupational respiratory-protection obligations, including fit testing when appropriate.

Consumables

Single use and disposal

Do not re-use disposable HD PPE; treat used PPE as potentially contaminated.

SOS example: ISO-MED sterile chemotherapy gowns. Its listing references AAMI Level 3 and provides a technical document, but approval requires checking the current permeation testing against the drugs and concentrations handled.

Controlled technique

Safe donning and doffing protect clean zones and personnel.

Effective PPE depends on when it is put on, how cuffs interface, where outer gloves are removed and how contaminated layers are discarded. Staff should practice the approved sequence rather than improvise. For double-gloving, the inner glove commonly sits beneath the gown cuff while the outer glove is placed over it, with adjustments for equipment-specific systems and qualified SOPs.

Step 01

Confirm supplies

Verify chemotherapy test claims, sterile status where applicable, sizes, gown performance and package integrity.

Step 02

Prepare hands and entry

Perform facility-specified hand hygiene and maintain clean gowning sequence.

Step 03

Don first barrier

Follow site-approved inner-glove placement and gowning order.

Step 04

Cover gown cuffs

Place the outer chemotherapy glove over the gown cuff as specified; check skin exposure after full-range movement.

Step 05

Control surface contacts

Keep hands in appropriate zones, avoid contaminated surfaces and change gloves when damaged or contaminated.

Step 06

Doff at the correct boundary

For sterile HD compounding, USP FAQ specifies outer gloves removed inside the C-PEC; remove gown/outer shoe covers in the negative-pressure doffing area.

Step 07

Dispose and complete hygiene

Use designated trace-HD waste where applicable, avoid touching outside surfaces, follow final PPE removal and perform hand hygiene.

Deactivation to disinfection

Four distinct operations control two different hazards: drugs and microbes.

The four stages should not be conflated. A disinfectant can be effective against microorganisms without neutralizing an HD. Alcohol disinfection is not necessarily drug deactivation, and a visible wipe-down does not prove that hazardous residues have been removed. The approved sequence depends on the specific drug, cleaning agent, location and sterile-compounding overlay.

Stage	Purpose	What to select / verify
1. Deactivation	Render the hazardous compound inactive where a suitable agent is known.	Drug-specific suitability, tested chemistry, surface compatibility and manufacturer instructions.
2. Decontamination	Physically remove or neutralize HD residue from non-disposable surfaces.	Qualified method and low-lint absorbent wipers, appropriate PPE, safe waste collection.
3. Cleaning	Remove organic and inorganic soils and other residues.	Compatible cleaner, validated application and rinse/dry steps where indicated.
4. Disinfection (where required)	Reduce microbial contamination in sterile compounding areas.	Appropriate registered disinfectant and sterile products where required; correct label contact time.

Critical practice: develop a surface-by-surface schedule, defined agent, dilution, wet contact time, wiping method, waste procedure and sign-off. When multiple chemicals are used sequentially, ensure compatibility and never mix incompatible disinfectants or oxidizers.

Agents and materials

Select the agent for its demonstrated function—not just the bottle label.

Choose based on the actual purpose. Sterile 70% IPA is commonly used in aseptic workflows, but it is not proven to neutralize all HDs and is not an all-purpose hazardous-drug deactivation product. Quaternary disinfectants may support microbial cleaning/disinfection under their EPA labels, but they do not automatically deactivate chemotherapy agents.

SOS catalog example	Why evaluate it	Limits and documentation
Texwipe TX650 TexQ sterile RTU 22 oz	EPA-registered quat cleaner/disinfectant with sterile packaging.	Use only for label-supported cleaning/disinfection; not proof of HD deactivation.
Texwipe TX652 TexQ sterile RTU gallon	Large format sterile quat cleaning/disinfection for controlled surfaces.	Qualify dispensing, chemical compatibility, contact time and sterile handling.
Texwipe TX3270 sterile 70% IPA 16 oz	Sterile alcohol for qualified aseptic disinfection/wipe-down.	Not an HD-neutralization guarantee; do not replace a required earlier deactivation/decontamination step.
Texwipe TX3285 sterile AlphaSat10 IPA wiper	Pre-wetted sterile polyester wipe that can standardize wetness in qualified steps.	Chemistry is IPA: it is not automatically an HD-specific deactivation material.
Texwipe TX3211 sterile dry polyester wiper	Sterile dry substrate may be suitable for defined cleaning/removal steps.	Qualified agent and area-specific procedure needed; never dry-wipe hazardous powder in a manner that aerosolizes it.
Chemo prep and spill mat category	Supplemental absorbent barrier on work surfaces.	Not a replacement for a spill kit, engineering controls or complete cleaning program.

Chemical surface monitoring

Use wipe sampling to identify trends and investigate contamination—not to claim “zero risk.”

HD environmental wipe sampling is recommended, not universally required, under USP’s 2026 FAQ. It can help establish a baseline and test whether containment and cleaning methods are controlling residual drug. It is a chemical surface-residue program, distinct from microbiological environmental monitoring under USP <797>. There is currently no universal acceptance limit for HD surface contamination in the FAQ.

Sampling plan

Choose representative sites

Include C-PEC interiors, frequently touched surfaces, transport points and locations where residue could migrate, as appropriate.

Analytes

Select meaningful marker drugs

Use a testing laboratory that can analyze drugs relevant to the facility and document the analytical method and detection limits.

Method

Use suitable sampling supplies

Qualified wipes/swabs, sampling area, recovery and transport methods must match the laboratory procedure.

Result

Interpret the context

A detected residue prompts documented investigation; no universal numeric “safe” threshold is established by the USP FAQ.

CAPA

Find and contain the cause

Review transfer, gloving, cleaning, C-PEC manipulation and equipment design; conduct corrective training and procedure changes.

Recheck

Verify effectiveness

Repeat appropriately planned sampling following corrective action where indicated.

For microbiological monitoring inside sterile areas, follow the USP 797 guide. See USP questions 48–51.

Spill readiness

Spill response requires a trained team, appropriate PPE and documented recovery.

A spill is an exposure event, not routine housekeeping. A response program should identify trained responders, access restrictions, PPE appropriate to the spill, cleanup methods, contained disposal, incident records and worker exposure procedures. Spill kits must be available in the relevant areas, but a prep mat is not a complete spill kit.

Step 01

Recognize and secure

Limit access, alert the designated response personnel and prevent uncontrolled foot traffic.

Step 02

Assess the substance and situation

Identify drug, amount, volatility, form and possible inhalation or skin risk; do not improvise cleanup.

Step 03

Use trained responders and PPE

Select gloves, gowns, eye/face and respiratory protection from the facility spill SOP and safety assessment.

Step 04

Contain and remove safely

Follow kit/SOP procedures, avoid aerosolization and ensure compatible absorbents and cleaning agents.

Step 05

Package waste and decontaminate

Collect used materials in the appropriate labeled HD waste and carry out prescribed cleaning steps.

Step 06

Document and follow up

Record cause, personnel involved, exposures, surface cleaning, occupational health actions and corrective steps.

Labeling and transport

A protected package is part of exposure control.

HD containment does not end when the medicine leaves the compounding enclosure. The final container, outer packaging, transport system and label must protect against leakage and inadvertent exposure. USP’s 2026 FAQ explicitly states that pneumatic tubes must not be used for any liquid HD or NIOSH Table 1 antineoplastic HD. Facilities must assess other transport modes and comply with carrier and regulatory labeling rules.

Packaging

Minimize breakage and leaks

Use compatible primary and secondary packaging; protect sterile integrity where required.

Labeling

Communicate handling precautions

Use the required HD and storage/disposal labels per approved policy and applicable law.

Transfer

Keep containers controlled

Avoid contaminated exterior contact with non-HD inventory or common surfaces.

Transport equipment

Evaluate cleanability

Use transport bins and carts that can be decontaminated and avoid inappropriate shared equipment.

Personnel

Train every receiver

Nursing, couriers, technicians and receiving personnel must know damage/spill escalation.

Documentation

Control exceptions

Record transport incidents, compromised packaging and corrective actions.

At point of care

Administration has separate glove, gown and CSTD requirements.

Administration controls depend on the drug and route. The USP 2026 FAQ requires two ASTM D6978-tested chemotherapy-glove pairs for administration of NIOSH Table 1 antineoplastic HDs and gowns shown to resist HD permeability for injectable Table 1 antineoplastics. CSTDs are required for administration of those HDs when the dosage form allows and must be compatible with the medication.

Activity	Exposure management	What to document
Preparing connection	Avoid drips, punctures or leaking connections.	PPE, CSTD/device compatibility and equipment checks.
Administering Table 1 antineoplastic HD	Two chemotherapy-glove pairs; appropriate gown for injectable agents.	Task protocol, training and patient-area spill response.
Disconnecting and waste	Control residual liquid, contaminated components and movement outside the patient-care area.	Disposal practices, incident and training records.
Handling other HDs	Apply facility-selected precautions according to the drug/task and Chapter <800> framework.	Assessment of risk and policies.

Hazardous waste

Trace and bulk HD waste require appropriate segregation and disposal.

Used gloves, gowns, wipes, mats and containers can carry residual HD. Waste classification depends on its contents and applicable federal, state and local requirements; trace versus bulk HD waste rules cannot be collapsed into a single generic bin instruction. The disposal workflow must be designated, labeled, secure and taught to handlers, cleaners and transport staff.

Before disposal

Separate at point of use

Provide the correct containers so staff need not carry contaminated PPE through clean areas.

Doffing

Remove within defined zones

Follow required C-PEC, C-SEC, anteroom and exit sequence; do not re-use disposable HD PPE.

Containers

Use compliant packaging

Keep waste secured and labeled under applicable waste and transport rules.

Cleaning staff

Train assigned personnel

Environmental services and waste-removal staff need suitable PPE and risk-based instruction.

Inspection

Avoid leakage and overfill

Check waste containers, lids, sharps containment, transfer routes and pickup processes.

Records

Retain disposal evidence

Use the documentation required for the type of HD waste and facility program.

Governance and quality

Make the program auditable, repeatable and owned.

A designated person—or persons, as assigned by the entity—oversees the organization’s HD program. The FAQ does not prescribe a universal number of training hours or require the designated person to be a pharmacist. Qualification is about capability, responsibility, documented policies, control of the environment and verification of competency.

Controlled record	What it demonstrates	Review trigger
Entity HD list and AoRs	Drug coverage and approved control rationale.	New formulations, new drugs, manufacturer warnings and list revisions.
Facility equipment records	C-PEC/C-SEC design, certification, preventive maintenance and pressure trends.	Scheduled certification, abnormal pressure and repairs.
Training and competency	Personnel can demonstrate task-specific HD handling and spill response.	New responsibilities, incidents or SOP changes.
Cleaning and wipe sampling	Execution and program effectiveness.	Detected residue, incomplete cleaning or product changes.
PPE and supply specifications	Approved exact SKUs, documentation and tested uses.	Supplier changes, stock substitutions and lot exceptions.
Deviation/CAPA	Causes investigated and actions verified.	Exposure, spill, contamination finding or equipment failure.

Occupational health

Medical surveillance supports—but cannot replace—effective exposure prevention.

Medical surveillance can help identify possible occupational health effects from hazardous-drug exposure. It complements engineering and procedural controls; it does not substitute for containment or prove that an individual is unexposed. Coordinate the program with qualified occupational health professionals and applicable law, including confidentiality and reproductive-risk concerns.

Scope

Identify exposed personnel

Consider staff involved in compounding, receiving, administration, cleaning, transport and waste.

Baseline

Appropriate health assessment

Use occupational health evaluation aligned to the substances and tasks handled.

Incidents

Prompt exposure follow-up

Document unexpected contact, needle sticks, spills and related follow-up per site protocols.

Trends

Review aggregate findings

Use outcomes and near misses to improve risk controls without disclosing individual private health information.

Reproductive risk

Provide clear information

Provide documented hazard communication and appropriate access to occupational health and individual consultation.

Prevention

Retain hierarchy of controls

Engineering and workplace practices remain primary protections; surveillance is a secondary safety mechanism.

Direct product links

SOSCleanroom consumables and PPE candidates for qualified HD workflows.

The following are live SOSCleanroom catalog examples identified for this guide. A listing is evidence that a particular candidate exists, not evidence of compliant performance for a specific drug, concentration, dose form or facility. Confirm manufacturer specifications, test data, size, sterile packaging, drug compatibility and current availability before purchasing.

Chemo PPE

ISO-MED Sterile Chemo Gowns

Sterile protective garment listing. Obtain the current drug permeability specification; AAMI Level 3 alone is not sufficient proof.

Sterile tested glove

Ansell TouchNTuff 93-700

Sterile nitrile glove candidate with manufacturer chemotherapy-test positioning. Verify exact ASTM D6978 permeation data.

Sterile tested glove

Ansell BioClean Excell BEXS

Cleanroom-processed sterile nitrile model. Review specific chemotherapy resistance and glove-cuff fit.

Sterile tested glove

Ansell BioClean Emerald BENS

Sterile nitrile glove listing with chemo-testing claim. Obtain manufacturer data for the drug list.

Sterile pair packed

TechNiGlove STN200P

Sterile pair-packed nitrile with published chemo-testing positioning; confirm drug-specific results.

Work-surface barrier

Ansell BioClean S-BCPM Prep Mats

Sterile absorbent three-layer prep mat for supplemental drip/transfer control; not a substitute for a C-PEC or spill kit.

Sterile IPA

Texwipe TX3270 16 oz

Sterile 70% IPA for qualified aseptic disinfection and wipe-down—not an HD deactivation guarantee.

Sterile IPA

Texwipe TX3273 32 oz

Larger sterile 70% IPA trigger format; evaluate task and lot documentation.

Sterile IPA

Texwipe TX3290 1 gallon

Sterile bulk 70% IPA for qualified high-volume use; dispensing method needs controls.

Sterile disinfectant

Texwipe TX650 TexQ 22 oz

EPA-registered sterile quat cleaner/disinfectant for labeled use; not generic chemotherapy deactivation.

Sterile disinfectant

Texwipe TX652 TexQ gallon

Large-format sterile quat for facility disinfection programs with proper dispensing controls.

Sterile wipe

Texwipe TX3285 AlphaSat10

Sterile sealed-border polyester pre-wetted 70% IPA wiper for qualified aseptic steps.

Sterile wipe

Texwipe TX3213 PolySat

Sterile pre-wetted polypropylene 70% IPA wipe for appropriate wipe-down tasks.

Sterile wipe

Texwipe TX3211 SterileWipe LP

Sterile dry polyester wipe for approved chemical application and residue removal methods.

Browse sterile products, chemo prep mats, sterile pre-wetted wipes and Ansell products.

Technical purchasing checklist

Build a defendable approved consumables list.

A purchasing team needs more than a brand name. HD programs should standardize the actual model, package presentation and performance evidence; substitutes change training, chemical protection, contamination profile and process compatibility. The same is true of a cleaning chemical marketed for pharmaceutical use: its registered efficacy, purpose and compatibility must match the approved procedure.

RFQ / approval field	Minimum useful detail
Application	HD receipt, sterile compounding, nonsterile compounding, administration, cleaning or spill support.
Drug/formulation	Relevant HDs, concentrations, diluents, solvents, surface types and contact/exposure modes.
Chemotherapy glove	Exact manufacturer/SKU, size, sterile status, ASTM D6978 permeation results, cuff length, package type and change interval evidence.
Chemo gown	Model, closure/cuff, seams, tested permeability, sterility if required and intended task.
Cleaning agent	Purpose (deactivation vs cleaning vs microbial disinfection), registered label, compatibility and contact time.
Wipers/mats	Material, sterile status, absorbency, particles, chemical compatibility and lot traceability.
Logistics	Case quantities, consumption by size, expiry, minimum remaining life, qualification documents and approved alternates.

Inspection readiness

Twenty areas to examine before the next review.

Use the items below to plan an internal review; they are educational prompts, not a declaration that completion means USP compliance. The linked existing PDF is a shorter 2026 worksheet; this expanded list is only in this page.

Self-assessment item	Evidence or action to check
01. Ownership	Designated responsible person(s), HD list governance and clear training authority.
02. Drug identification	Current NIOSH 2024 publication, subsequent notices and manufacturer labels evaluated.
03. Assessment of risk	Written drug- and dosage-form-specific AoRs where allowed, approved and reviewed.
04. Receiving	Assigned unpacking area, package checks, PPE and breakage procedure.
05. Storage	Controlled designated HD storage; dedicated refrigeration and ventilation when applicable.
06. Engineering	Appropriate C-PEC and C-SEC documentation, certification and exhaust arrangements.
07. Air balance	Continuous negative pressure, ACPH and alert/escalation procedure.
08. C-SCA	Category 1 HD CSP-only pathway evaluated for eligible operations.
09. Sterile overlay	USP 797 qualification, environmental controls and aseptic competency addressed for sterile HDs.
10. Gloves	Two ASTM D6978-tested pairs for HD compounding; drug-specific permeation and fit assessed.
11. Gowns	HD permeability evidence verified; correct garment and shoe-cover process.
12. CSTDs	Correct compounding/admin use rules, device/HD compatibility and training.
13. Four cleaning stages	Agent, surface, purpose, technique, contact time, PPE and waste defined.
14. Monitoring	HD wipe sampling plan considered; results and follow-up managed.
15. Spill readiness	Supplies accessible, responders trained and incidents logged.
16. Transport	Breakage/leakage controls, labeling and pneumatic-tube restrictions in SOP.
17. Disposal	Trace/bulk waste separation and staff training per law and policy.
18. Occupational health	Exposure reporting and medical-surveillance program reviewed with qualified personnel.
19. Procurement	Approved exact SKUs, certificates, lot tracking, substitution controls and stock continuity.
20. CAPA	Out-of-limit events trigger documented investigation, corrective action and effectiveness check.

Printable companion: SOSCleanroom USP 800 customer checklist (PDF). Official verification: USP FAQ (January 2026).

Practice-based training

Eight realistic scenarios for staff training and SOP review.

Scenario A

Damaged chemotherapy shipment

A receiving associate finds a wet exterior carton. Keep it from the clean suite, use the defined package-response pathway and document the incident; do not open it casually.

Scenario B

Sterile antineoplastic IV preparation

Two ASTM D6978-tested glove layers are required and the outer glove barrier must support sterile technique; a negative-pressure room alone does not make the procedure sterile.

Scenario C

Nonsterile HD API powder

Weighing powder creates airborne exposure potential. Use approved source containment and dedicated equipment rather than relying only on an N95 or double gloves.

Scenario D

CSTD selection

A compatible CSTD may be required for Table 1 antineoplastic administration when dosage form allows; it never substitutes for the C-PEC during compounding.

Scenario E

Residual drug on a clean bench

Do not assume a sterile 70% IPA pass deactivates the residue. Use the approved deactivation/decontamination/cleaning sequence and investigate the source.

Scenario F

New gown substitute

A sterile gown marketed as AAMI Level 3 is not automatically adequate for every HD. Obtain current drug permeability documentation before approval.

Scenario G

Contaminated prep mat

A pad captures drips, but may transfer HD residue during removal. Follow site change timing, PPE and waste pathway.

Scenario H

Air pressure alarm after hours

Room containment depends on continuous pressure and ventilation; follow escalation, product-risk evaluation and facility restart requirements.

Frequently asked questions

Practical answers for pharmacy, facilities, EHS and procurement teams.

Does USP <800> apply only to sterile compounding?

No. It applies to relevant HD handling throughout receipt, storage, compounding, dispensing, administration, transport and disposal.

Is the 2024 NIOSH list the current publication?

Yes, the NIOSH 2024 list (publication 2025-103) supersedes the 2016 list; consult CDC additions and notices.

Is every drug in NIOSH Table 1 an antineoplastic?

No. The 2024 Table 1 includes other qualifying drugs. USP uses the relevant antineoplastic classification for its Table 1 antineoplastic rules.

Can every hazardous drug be exempted by an assessment of risk?

No. HD APIs and qualifying Table 1 antineoplastics requiring manipulation have containment obligations. Other situations may qualify for an AoR under the chapter.

Are two chemotherapy-glove pairs required for HD compounding?

Yes. The January 2026 USP FAQ confirms two ASTM D6978-compliant pairs for both sterile and nonsterile HD compounding.

Does every HD task require two glove pairs?

No. Receiving and administering have task-specific rules. For unpacking Table 1 antineoplastics, at least one ASTM D6978 pair is required.

Does a sterile glove automatically meet ASTM D6978?

No. Sterility and chemotherapy permeation performance are separate documented attributes.

Is an AAMI Level 3 sterile gown automatically a chemo gown?

No. Verify manufacturer permeability performance against relevant hazardous drugs; AAMI fluid-barrier level by itself is not enough.

Does the inner glove always go over the gown cuff?

No. In a typical double-glove system the inner glove sits beneath and the outer glove over the gown cuff, subject to approved SOP and isolator design.

Is a CSTD required when compounding?

USP 2026 FAQ says recommended for HD compounding but not universally required. It is required for Table 1 antineoplastic administration when the dosage form allows.

Can a CACI eliminate the need for a C-SEC?

No. The USP 2026 FAQ states an appropriate CACI still must be located inside an eligible C-SEC.

Can Category 2 or 3 sterile HD CSPs be made in a C-SCA?

No. The January 2026 FAQ specifies only Category 1 HD CSPs can be prepared in a C-SCA.

May HD room negative pressure be switched off when unused?

No. C-SEC containment pressure and appropriate air changes are continuous design requirements.

Is HD environmental wipe sampling mandatory?

The USP 2026 FAQ recommends wipe sampling but does not universally require it; the program can assess effectiveness and detect contamination trends.

Is there a universal safe HD residue limit on surfaces?

No. The USP 2026 FAQ notes no standard acceptable surface contamination limit; sampling results need investigation and context.

Can sterile 70% IPA deactivate all chemotherapy residues?

No. IPA is not universally validated to deactivate hazardous drugs; deactivation, decontamination, cleaning and disinfection have different purposes.

Can liquid hazardous drugs be sent by pneumatic tube?

No. USP 2026 FAQ prohibits pneumatic tube transport for any liquid HD and for Table 1 antineoplastic HDs.

Can a used HD gown be stored for reuse later that day?

No. The USP FAQ states disposable HD PPE must not be reused.

Does SOSCleanroom certify a facility as compliant?

No. SOSCleanroom provides products and education; facilities and qualified personnel determine compliance through applicable standards, SOPs and regulations.

Primary technical references

Verify requirements against USP, NIOSH, ASTM and manufacturer sources.

These sources were used to cross-check high-consequence claims. The official standards must be consulted before implementation; USP FAQs are technical-support explanations and not themselves official interpretation or compliance certificates. Some full texts require a license.

Publisher / document	What it supports
Official USP–NF <800> chapter pathway	The authoritative licensed general chapter for HD handling.
USP <800> FAQ, updated January 21, 2026	AoR, C-SCA Category 1, engineering, double gloving, CSTD, wipe sampling, receiving and transport clarifications.
NIOSH List of Hazardous Drugs in Healthcare Settings, 2024	Current published HD list, table arrangement and official additions.
NIOSH Managing Hazardous Drug Exposures	Exposure pathways, risk-management scenarios and occupational protection.
ASTM D6978-05(2023) chemotherapy-glove permeation	Chemotherapy-drug permeation assessment; purchase full test publication if required.
ASTM F3267-22 chemo-protective clothing	Referenced protective-clothing specification for liquid chemotherapy/other liquid HD exposure.
Texwipe pharmaceutical compounding cleaning brochure	Manufacturer application context; compare against current labels and note older cited product items may be discontinued.
SOSCleanroom January 2026 HD checklist	Retained printable earlier checklist, shorter than this full guide.
SOS sterile chemo gown product and test-document links	Candidate garment construction and performance evidence requiring exact drug evaluation.

Editorial review date: October 28, 2026. Verify manufacturer documents and legal/compendial changes before any operational adoption.

SOSCLEANROOM | HAZARDOUS-DRUG SUPPLY STANDARDIZATION

Select Chemo PPE, Wipers & Cleaning Materials With Documented Purpose.

Share your exact drug handling tasks, sterile or nonsterile process, approved glove/gown requirements, cleaning chemicals, surface types, pack formats, sizes and estimated usage. SOSCleanroom can identify candidate items and help with recurring supply continuity while your facility retains responsibility for formal product qualification and safe work practices.

Request a Hazardous-Drug Supply Quote → Browse Sterile Products →

Contact our team: 800-443-7101

Educational scope and limitations: Reviewed October 28, 2026. This is an educational and purchasing reference, not medical, legal, regulatory, occupational-safety or pharmacy practice advice; not the official USP–NF chapter; not a facility SOP; and not a certification that products or facilities comply with USP standards. The currently applicable licensed chapter, jurisdictional law, manufacturer instructions, chemical compatibility, trained professionals and qualified facility procedures control. Product listings and availability may change.